Business Standard

Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug

Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly

Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters
Premium

Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters

Sohini Das Mumbai,
US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
 
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.  
 
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 11 2021 | 12:53 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com